Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features
- PMID: 20131996
- DOI: 10.1586/era.09.189
Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features
Abstract
Review of the spectrum of breast cancer tumor subtypes, which include basal-like, triple-negative and BRCA1-positive tumors, suggest that they have overlapping clinical, pathologic and molecular features, which are different from endocrine responsive breast cancers. Although response to chemotherapy is high in the neoadjuvant setting, the overall prognosis of this subset of tumors remains poor. Gene-profiling studies of this heterogeneous subset have lead to a better understanding of the molecular pathology of these aggressive tumors and the identification of possible therapeutic targets. Ongoing clinical studies of newer targeted agents, along with optimal chemotherapy, portend an improved clinical outcome for patients with aggressive basal-like/triple-negative breast cancer in the future.
Similar articles
-
What is triple-negative breast cancer?Eur J Cancer. 2008 Dec;44(18):2799-805. doi: 10.1016/j.ejca.2008.09.034. Epub 2008 Nov 12. Eur J Cancer. 2008. PMID: 19008097 Review.
-
Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.Adv Anat Pathol. 2007 Nov;14(6):419-30. doi: 10.1097/PAP.0b013e3181594733. Adv Anat Pathol. 2007. PMID: 18049131 Review.
-
Pharmacotherapy of triple-negative breast cancer.Expert Opin Pharmacother. 2009 Sep;10(13):2081-93. doi: 10.1517/14656560903117309. Expert Opin Pharmacother. 2009. PMID: 19640211 Review.
-
Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options.Clin Breast Cancer. 2008 Dec;8 Suppl 4:S171-8. doi: 10.3816/CBC.2008.s.014. Clin Breast Cancer. 2008. PMID: 19158038 Review.
-
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res. 2007 Apr 15;13(8):2329-34. doi: 10.1158/1078-0432.CCR-06-1109. Clin Cancer Res. 2007. PMID: 17438091
Cited by
-
Hormone receptors and age distribution in breast cancer patients at a university hospital in northern egypt.Breast Cancer (Auckl). 2013 Jun 12;7:51-7. doi: 10.4137/BCBCR.S12214. Print 2013. Breast Cancer (Auckl). 2013. PMID: 23825439 Free PMC article.
-
Overexpression of BIRC6 driven by EGF-JNK-HECTD1 signaling is a potential therapeutic target for triple-negative breast cancer.Mol Ther Nucleic Acids. 2021 Sep 28;26:798-812. doi: 10.1016/j.omtn.2021.09.011. eCollection 2021 Dec 3. Mol Ther Nucleic Acids. 2021. PMID: 34729249 Free PMC article.
-
MEGF11 is related to tumour recurrence in triple negative breast cancer via chemokine upregulation.Sci Rep. 2020 May 15;10(1):8060. doi: 10.1038/s41598-020-64950-0. Sci Rep. 2020. PMID: 32415115 Free PMC article.
-
Copy number amplification of ENSA promotes the progression of triple-negative breast cancer via cholesterol biosynthesis.Nat Commun. 2022 Feb 10;13(1):791. doi: 10.1038/s41467-022-28452-z. Nat Commun. 2022. PMID: 35145111 Free PMC article.
-
Reinventing diagnostics for personalized therapy in oncology.Cancers (Basel). 2010 Jun 2;2(2):1066-91. doi: 10.3390/cancers2021066. Cancers (Basel). 2010. PMID: 24281107 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous